Undervalued Penny Stocks To Consider In October 2026

Over the last 7 days, the market has dropped 1.0%, but it is up 11% over the past year, with earnings forecasted to grow by 17% annually. In light of these conditions, identifying stocks that combine strong financial health with growth potential can be particularly rewarding. Penny stocks—often representing smaller or newer companies—remain an intriguing investment area as they can offer unexpected opportunities for returns when backed by solid fundamentals.

Let's explore several standout options from the results in the screener.

Telos (TLS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Telos Corporation, along with its subsidiaries, offers cyber, cloud, and enterprise security solutions both in the United States and internationally, with a market cap of approximately $304.18 million.

Operations: The company's revenue is derived from Secure Networks, which generated $9.77 million, and Security Solutions, contributing $183.94 million.

Market Cap: $304.18M

Telos Corporation, with a market cap of approximately US$304.18 million, has been actively securing significant contracts in the cybersecurity sector, including recent awards from the U.S. Department of Commerce and Health and Human Services. Despite being unprofitable with a negative return on equity (-16.85%), Telos maintains a strong financial position with no debt and sufficient cash runway for over three years due to positive free cash flow growth. The company has not experienced meaningful shareholder dilution recently but faced insider selling in the past quarter. Its seasoned management team continues to drive strategic partnerships across federal agencies, enhancing its revenue prospects through its FedRAMP Class D (High)-authorized Xacta platform offerings.

• Take a closer look at Telos' potential here in our financial health report.
• Explore Telos' analyst forecasts in our growth report.

Outset Medical (OM)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Outset Medical, Inc. is a medical technology company focused on developing a hemodialysis system for use in the United States, with a market cap of $56.39 million.

Operations: The company's revenue is primarily generated from its Surgical & Medical Equipment segment, totaling $117.80 million.

Market Cap: $56.39M

Outset Medical, Inc., with a market cap of US$56.39 million, has shown resilience in its financials despite being unprofitable and having a negative return on equity (-77.12%). The company reported revenue of US$31.64 million for Q2 2026, slightly up from the previous year. It maintains a strong cash position with short-term assets exceeding liabilities and more cash than debt, ensuring over three years of cash runway at current free cash flow levels. Although losses have reduced by 10.1% annually over five years, volatility remains high and profitability isn't anticipated soon despite stable shareholder dilution trends and experienced board oversight.

• Click to explore a detailed breakdown of our findings in Outset Medical's financial health report.
• Review our growth performance report to gain insights into Outset Medical's future.

CI&T (CINT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: CI&T Inc. offers strategy, design, and software engineering services globally, with a market cap of $392.93 million.

Operations: The company's revenue primarily comes from its Computer Services segment, which generated $541.02 million.

Market Cap: $392.93M

CI&T Inc., with a market cap of US$392.93 million, is navigating the penny stock landscape with strategic initiatives and solid financial metrics. The company recently launched CI&T Business Builders to enhance AI-driven business processes, indicating a focus on innovation and expansion in key sectors like financial services and healthcare. Despite being dropped from the S&P Global BMI Index, CI&T raised its earnings guidance for 2026, forecasting revenue between US$565.5 million and US$577.8 million. Financially sound, it has strong interest coverage (6.6x EBIT) and manageable debt levels (25.4% net debt to equity), although profit margins have slightly declined year-over-year.

• Unlock comprehensive insights into our analysis of CI&T stock in this financial health report.
• Learn about CI&T's future growth trajectory here.

Next Steps

• Jump into our full catalog of 315 US Penny Stocks here.
• Curious About Other Options? Uncover 26 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com